Insider · CIK 0001818245
Laxminarayan Bhat
Files at RVPH (REVIVA PHARMACEUTICALS HOLDINGS, INC.). First filing -, latest -.
In brief
Laxminarayan Bhat files SEC Form 4 as CEO, president, director and 10% owner at RVPH (REVIVA PHARMACEUTICALS HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Laxminarayan Bhat has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivative | +109,150 | $0.00 | $0 | 109,150 | Mar 20, 2026 |
| Mar 18, 2026 | RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +40,925 | $0.00 | $0 | 40,925 | Mar 20, 2026 |
| Feb 13, 2025 | RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivative | +519,000 | $0.00 | $0 | 519,000 | Feb 18, 2025 |
| Feb 13, 2025 | RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +181,500 | $0.00 | $0 | 181,500 | Feb 18, 2025 |
Questions about Laxminarayan Bhat
Answered from the filings on this page, as of the latest one.
Is Laxminarayan Bhat buying or selling?
Laxminarayan Bhat has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Laxminarayan Bhat's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Laxminarayan Bhat has 0.
Where does Laxminarayan Bhat file Form 4?
Laxminarayan Bhat has filed Form 4 at RVPH (REVIVA PHARMACEUTICALS HOLDINGS, INC.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.